Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort.

Oncotarget

Raskin L, Guo Y, Du L, Clendenning M, Rosty C, Lindor NM, Gruber SB, Buchanan DD.
PMID: 29212164
Oncotarget. 2017 Jun 21;8(55):93450-93463. doi: 10.18632/oncotarget.18596. eCollection 2017 Nov 07.

The underlying genetic cause of colorectal cancer (CRC) can be identified for 5-10% of all cases, while at least 20% of CRC cases are thought to be due to inherited genetic factors. Screening for highly penetrant mutations in genes...

Cite
Raskin L, Guo Y, Du L, et al. Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort. Oncotarget. 2017;8(55):93450-93463doi: 10.18632/oncotarget.18596.
Raskin, L., Guo, Y., Du, L., Clendenning, M., Rosty, C., Lindor, N. M., Gruber, S. B., & Buchanan, D. D. (2017). Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort. Oncotarget, 8(55), 93450-93463. https://doi.org/10.18632/oncotarget.18596
Raskin, Leon, et al. "Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort." Oncotarget vol. 8,55 (2017): 93450-93463. doi: https://doi.org/10.18632/oncotarget.18596
Raskin L, Guo Y, Du L, Clendenning M, Rosty C, Lindor NM, Gruber SB, Buchanan DD. Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort. Oncotarget. 2017 Jun 21;8(55):93450-93463. doi: 10.18632/oncotarget.18596. eCollection 2017 Nov 07. PMID: 29212164; PMCID: PMC5706810.
Copy Download .nbib Format: NLM
Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Wang X, Su YR, Petersen PS, Bien S, Schmit SL, Drew DA, Albanes D, Berndt SI, Brenner H, Campbell PT, Casey G, Chang-Claude J, Gallinger SJ, Gruber SB, Haile RW, Harrison TA, Hoffmeister M, Jacobs EJ, Jenkins MA, Joshi AD, Li L, Lin Y, Lindor NM, Marchand LL, Martin V, Milne R, Maclnnis R, Moreno V, Nan H, Newcomb PA, Potter JD, Rennert G, Rennert H, Slattery ML, Thibodeau SN, Weinstein SJ, Woods MO, Chan AT, White E, Hsu L, Peters U.
PMID: 32651213
Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1800-1808. doi: 10.1158/1055-9965.EPI-19-1018. Epub 2020 Jul 10.

BACKGROUND: Regular use of nonsteroidal anti-inflammatory drugs (NSAID) is associated with lower risk of colorectal cancer. Genome-wide interaction analysis on single variants (G × E) has identified several SNPs that may interact with NSAIDs to confer colorectal cancer risk,...

Cite
Wang X, Su YR, Petersen PS, et al. Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020;29(9):1800-1808doi: 10.1158/1055-9965.EPI-19-1018.
Wang, X., Su, Y. R., Petersen, P. S., Bien, S., Schmit, S. L., Drew, D. A., Albanes, D., Berndt, S. I., Brenner, H., Campbell, P. T., Casey, G., Chang-Claude, J., Gallinger, S. J., Gruber, S. B., Haile, R. W., Harrison, T. A., Hoffmeister, M., Jacobs, E. J., Jenkins, M. A., Joshi, A. D., Li, L., Lin, Y., Lindor, N. M., Marchand, L. L., Martin, V., Milne, R., Maclnnis, R., Moreno, V., Nan, H., Newcomb, P. A., Potter, J. D., Rennert, G., Rennert, H., Slattery, M. L., Thibodeau, S. N., Weinstein, S. J., Woods, M. O., Chan, A. T., White, E., Hsu, L., & Peters, U. (2020). Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 29(9), 1800-1808. https://doi.org/10.1158/1055-9965.EPI-19-1018
Wang, Xiaoliang, et al. "Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 29,9 (2020): 1800-1808. doi: https://doi.org/10.1158/1055-9965.EPI-19-1018
Wang X, Su YR, Petersen PS, Bien S, Schmit SL, Drew DA, Albanes D, Berndt SI, Brenner H, Campbell PT, Casey G, Chang-Claude J, Gallinger SJ, Gruber SB, Haile RW, Harrison TA, Hoffmeister M, Jacobs EJ, Jenkins MA, Joshi AD, Li L, Lin Y, Lindor NM, Marchand LL, Martin V, Milne R, Maclnnis R, Moreno V, Nan H, Newcomb PA, Potter JD, Rennert G, Rennert H, Slattery ML, Thibodeau SN, Weinstein SJ, Woods MO, Chan AT, White E, Hsu L, Peters U. Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1800-1808. doi: 10.1158/1055-9965.EPI-19-1018. Epub 2020 Jul 10. PMID: 32651213; PMCID: PMC7556991.
Copy Download .nbib Format: NLM
Accounting for misclassification in electronic health records-derived exposures using generalized linear finite mixture models.

Health services & outcomes research methodology

Hubbard RA, Johnson E, Chubak J, Wernli KJ, Kamineni A, Bogart A, Rutter CM.
PMID: 28943779
Health Serv Outcomes Res Methodol. 2017 Jun;17(2):101-112. doi: 10.1007/s10742-016-0149-5. Epub 2016 Jun 03.

Exposures derived from electronic health records (EHR) may be misclassified, leading to biased estimates of their association with outcomes of interest. An example of this problem arises in the context of cancer screening where test indication, the purpose for...

Cite
Hubbard RA, Johnson E, Chubak J, et al. Accounting for misclassification in electronic health records-derived exposures using generalized linear finite mixture models. Health Serv Outcomes Res Methodol. 2016;17(2):101-112doi: 10.1007/s10742-016-0149-5.
Hubbard, R. A., Johnson, E., Chubak, J., Wernli, K. J., Kamineni, A., Bogart, A., & Rutter, C. M. (2017). Accounting for misclassification in electronic health records-derived exposures using generalized linear finite mixture models. Health services & outcomes research methodology, 17(2), 101-112. https://doi.org/10.1007/s10742-016-0149-5
Hubbard, Rebecca A, et al. "Accounting for misclassification in electronic health records-derived exposures using generalized linear finite mixture models." Health services & outcomes research methodology vol. 17,2 (2017): 101-112. doi: https://doi.org/10.1007/s10742-016-0149-5
Hubbard RA, Johnson E, Chubak J, Wernli KJ, Kamineni A, Bogart A, Rutter CM. Accounting for misclassification in electronic health records-derived exposures using generalized linear finite mixture models. Health Serv Outcomes Res Methodol. 2017 Jun;17(2):101-112. doi: 10.1007/s10742-016-0149-5. Epub 2016 Jun 03. PMID: 28943779; PMCID: PMC5608281.
Copy Download .nbib Format: NLM
Risk Models for Breast Cancer and Their Validation.

Statistical science : a review journal of the Institute of Mathematical Statistics

Brentnall AR, Cuzick J.
PMID: 32226220
Stat Sci. 2020 Mar 03;35(1):14-30. doi: 10.1214/19-STS729.

Strategies to prevent cancer and diagnose it early when it is most treatable are needed to reduce the public health burden from rising disease incidence. Risk assessment is playing an increasingly important role in targeting individuals in need of...

Cite
Brentnall AR, Cuzick J. Risk Models for Breast Cancer and Their Validation. Stat Sci. 2020;35(1):14-30doi: 10.1214/19-STS729.
Brentnall, A. R., & Cuzick, J. (2020). Risk Models for Breast Cancer and Their Validation. Statistical science : a review journal of the Institute of Mathematical Statistics, 35(1), 14-30. https://doi.org/10.1214/19-STS729
Brentnall, Adam R, and Cuzick, Jack. "Risk Models for Breast Cancer and Their Validation." Statistical science : a review journal of the Institute of Mathematical Statistics vol. 35,1 (2020): 14-30. doi: https://doi.org/10.1214/19-STS729
Brentnall AR, Cuzick J. Risk Models for Breast Cancer and Their Validation. Stat Sci. 2020 Mar 03;35(1):14-30. doi: 10.1214/19-STS729. PMID: 32226220; PMCID: PMC7100774.
Copy Download .nbib Format: NLM
Genetically Inferred Telomere Length and Testicular Germ Cell Tumor Risk.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Brown DW, Lan Q, Rothman N, Pluta J, Almstrup K, Dalgaard MD, Greene MH, Grotmol T, Loveday C, Schwartz SM, Turnbull C, Wiklund F, Kanetsky PA, Nathanson KL, McGlynn KA, Machiela MJ.
PMID: 33737296
Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1275-1278. doi: 10.1158/1055-9965.EPI-20-1775. Epub 2021 Mar 18.

BACKGROUND: Studies evaluating the association between peripheral blood leukocyte telomere length (LTL) and testicular germ cell tumor (TGCT) risk have produced conflicting results.METHODS: Using available genotype data from the Testicular Cancer Consortium (TECAC), polygenic risk score and Mendelian randomization...

Cite
Brown DW, Lan Q, Rothman N, et al. Genetically Inferred Telomere Length and Testicular Germ Cell Tumor Risk. Cancer Epidemiol Biomarkers Prev. 2021;30(6):1275-1278doi: 10.1158/1055-9965.EPI-20-1775.
Brown, D. W., Lan, Q., Rothman, N., Pluta, J., Almstrup, K., Dalgaard, M. D., Greene, M. H., Grotmol, T., Loveday, C., Schwartz, S. M., Turnbull, C., Wiklund, F., Kanetsky, P. A., Nathanson, K. L., McGlynn, K. A., Machiela, M. J. (2021). Genetically Inferred Telomere Length and Testicular Germ Cell Tumor Risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(6), 1275-1278. https://doi.org/10.1158/1055-9965.EPI-20-1775
Brown, Derek W, et al. "Genetically Inferred Telomere Length and Testicular Germ Cell Tumor Risk." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,6 (2021): 1275-1278. doi: https://doi.org/10.1158/1055-9965.EPI-20-1775
Brown DW, Lan Q, Rothman N, Pluta J, Almstrup K, Dalgaard MD, Greene MH, Grotmol T, Loveday C, Schwartz SM, Turnbull C, Wiklund F, Kanetsky PA, Nathanson KL, McGlynn KA, Machiela MJ. Genetically Inferred Telomere Length and Testicular Germ Cell Tumor Risk. Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1275-1278. doi: 10.1158/1055-9965.EPI-20-1775. Epub 2021 Mar 18. PMID: 33737296; PMCID: PMC8172526.
Copy Download .nbib Format: NLM
Genetically Inferred Telomere Length and Testicular Germ Cell Tumor Risk.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Brown DW, Lan Q, Rothman N, Pluta J, Almstrup K, Dalgaard MD, Greene MH, Grotmol T, Loveday C, Schwartz SM, Turnbull C, Wiklund F, Kanetsky PA, Nathanson KL, McGlynn KA, Machiela MJ.
PMID: 33737296
Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1275-1278. doi: 10.1158/1055-9965.EPI-20-1775. Epub 2021 Mar 18.

BACKGROUND: Studies evaluating the association between peripheral blood leukocyte telomere length (LTL) and testicular germ cell tumor (TGCT) risk have produced conflicting results.METHODS: Using available genotype data from the Testicular Cancer Consortium (TECAC), polygenic risk score and Mendelian randomization...

Cite
Brown DW, Lan Q, Rothman N, et al. Genetically Inferred Telomere Length and Testicular Germ Cell Tumor Risk. Cancer Epidemiol Biomarkers Prev. 2021;30(6):1275-1278doi: 10.1158/1055-9965.EPI-20-1775.
Brown, D. W., Lan, Q., Rothman, N., Pluta, J., Almstrup, K., Dalgaard, M. D., Greene, M. H., Grotmol, T., Loveday, C., Schwartz, S. M., Turnbull, C., Wiklund, F., Kanetsky, P. A., Nathanson, K. L., McGlynn, K. A., Machiela, M. J. (2021). Genetically Inferred Telomere Length and Testicular Germ Cell Tumor Risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(6), 1275-1278. https://doi.org/10.1158/1055-9965.EPI-20-1775
Brown, Derek W, et al. "Genetically Inferred Telomere Length and Testicular Germ Cell Tumor Risk." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,6 (2021): 1275-1278. doi: https://doi.org/10.1158/1055-9965.EPI-20-1775
Brown DW, Lan Q, Rothman N, Pluta J, Almstrup K, Dalgaard MD, Greene MH, Grotmol T, Loveday C, Schwartz SM, Turnbull C, Wiklund F, Kanetsky PA, Nathanson KL, McGlynn KA, Machiela MJ. Genetically Inferred Telomere Length and Testicular Germ Cell Tumor Risk. Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1275-1278. doi: 10.1158/1055-9965.EPI-20-1775. Epub 2021 Mar 18. PMID: 33737296; PMCID: PMC8172526.
Copy Download .nbib Format: NLM
Predictors of preoperative MRI for breast cancer: differences by data source.

Journal of comparative effectiveness research

Loggers ET, Gao H, Gold LS, Kessler L, Etzioni R, Buist DS.
PMID: 25960128
J Comp Eff Res. 2015 May;4(3):215-226. doi: 10.2217/cer.15.1. Epub 2015 May 11.

AIM: Investigate how the results of predictive models of preoperative MRI for breast cancer change based on available data.MATERIALS & METHODS: A total of 1919 insured women aged ≥18 with stage 0-III breast cancer diagnosed 2002-2009. Four models were...

Cite
Loggers ET, Gao H, Gold LS, et al. Predictors of preoperative MRI for breast cancer: differences by data source. J Comp Eff Res. 2015;4(3):215-226doi: 10.2217/cer.15.1.
Loggers, E. T., Gao, H., Gold, L. S., Kessler, L., Etzioni, R., Buist, D. S. (2015). Predictors of preoperative MRI for breast cancer: differences by data source. Journal of comparative effectiveness research, 4(3), 215-226. https://doi.org/10.2217/cer.15.1
Loggers, Elizabeth T, et al. "Predictors of preoperative MRI for breast cancer: differences by data source." Journal of comparative effectiveness research vol. 4,3 (2015): 215-226. doi: https://doi.org/10.2217/cer.15.1
Loggers ET, Gao H, Gold LS, Kessler L, Etzioni R, Buist DS. Predictors of preoperative MRI for breast cancer: differences by data source. J Comp Eff Res. 2015 May;4(3):215-226. doi: 10.2217/cer.15.1. Epub 2015 May 11. PMID: 25960128; PMCID: PMC4641841.
Copy Download .nbib Format: NLM
Advanced Imaging and Receipt of Guideline Concordant Care in Women with Early Stage Breast Cancer.

International journal of breast cancer

Loggers ET, Buist DS, Gold LS, Zeliadt S, Hunter Merrill R, Etzioni R, Ramsey SD, Sullivan SD, Kessler L.
PMID: 27525122
Int J Breast Cancer. 2016;2016:2182985. doi: 10.1155/2016/2182985. Epub 2016 Jul 25.

Objective. It is unknown whether advanced imaging (AI) is associated with higher quality breast cancer (BC) care. Materials and Methods. Claims and Surveillance Epidemiology and End Results data were linked for women diagnosed with incident stage I-III BC between...

Cite
Loggers ET, Buist DS, Gold LS, et al. Advanced Imaging and Receipt of Guideline Concordant Care in Women with Early Stage Breast Cancer. Int J Breast Cancer. 2016;2016:2182985doi: 10.1155/2016/2182985.
Loggers, E. T., Buist, D. S., Gold, L. S., Zeliadt, S., Hunter Merrill, R., Etzioni, R., Ramsey, S. D., Sullivan, S. D., & Kessler, L. (2016). Advanced Imaging and Receipt of Guideline Concordant Care in Women with Early Stage Breast Cancer. International journal of breast cancer, 20162182985. https://doi.org/10.1155/2016/2182985
Loggers, Elizabeth Trice, et al. "Advanced Imaging and Receipt of Guideline Concordant Care in Women with Early Stage Breast Cancer." International journal of breast cancer vol. 2016 (2016): 2182985. doi: https://doi.org/10.1155/2016/2182985
Loggers ET, Buist DS, Gold LS, Zeliadt S, Hunter Merrill R, Etzioni R, Ramsey SD, Sullivan SD, Kessler L. Advanced Imaging and Receipt of Guideline Concordant Care in Women with Early Stage Breast Cancer. Int J Breast Cancer. 2016;2016:2182985. doi: 10.1155/2016/2182985. Epub 2016 Jul 25. PMID: 27525122; PMCID: PMC4976155.
Copy Download .nbib Format: NLM
Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study.

JMIR cancer

A'mar T, Beatty JD, Fedorenko C, Markowitz D, Corey T, Lange J, Schwartz SM, Huang B, Chubak J, Etzioni R.
PMID: 32804084
JMIR Cancer. 2020 Aug 17;6(2):e18143. doi: 10.2196/18143.

BACKGROUND: There is a need for automated approaches to incorporate information on cancer recurrence events into population-based cancer registries.OBJECTIVE: The aim of this study is to determine the accuracy of a novel data mining algorithm to extract information from...

Cite
A'mar T, Beatty JD, Fedorenko C, et al. Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study. JMIR Cancer. 2020;6(2):e18143doi: 10.2196/18143.
A'mar, T., Beatty, J. D., Fedorenko, C., Markowitz, D., Corey, T., Lange, J., Schwartz, S. M., Huang, B., Chubak, J., & Etzioni, R. (2020). Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study. JMIR cancer, 6(2), e18143. https://doi.org/10.2196/18143
A'mar, Teresa, et al. "Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study." JMIR cancer vol. 6,2 (2020): e18143. doi: https://doi.org/10.2196/18143
A'mar T, Beatty JD, Fedorenko C, Markowitz D, Corey T, Lange J, Schwartz SM, Huang B, Chubak J, Etzioni R. Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study. JMIR Cancer. 2020 Aug 17;6(2):e18143. doi: 10.2196/18143. PMID: 32804084; PMCID: PMC7459434.
Copy Download .nbib Format: NLM
The Cancer Research Network: a platform for epidemiologic and health services research on cancer prevention, care, and outcomes in large, stable populations.

Cancer causes & control : CCC

Chubak J, Ziebell R, Greenlee RT, Honda S, Hornbrook MC, Epstein M, Nekhlyudov L, Pawloski PA, Ritzwoller DP, Ghai NR, Feigelson HS, Clancy HA, Doria-Rose VP, Kushi LH.
PMID: 27639398
Cancer Causes Control. 2016 Nov;27(11):1315-1323. doi: 10.1007/s10552-016-0808-4. Epub 2016 Sep 17.

PURPOSE: The ability to collect data on patients for long periods prior to, during, and after a cancer diagnosis is critical for studies of cancer etiology, prevention, treatment, outcomes, and costs. We describe such data capacities within the Cancer...

Cite
Chubak J, Ziebell R, Greenlee RT, et al. The Cancer Research Network: a platform for epidemiologic and health services research on cancer prevention, care, and outcomes in large, stable populations. Cancer Causes Control. 2016;27(11):1315-1323doi: 10.1007/s10552-016-0808-4.
Chubak, J., Ziebell, R., Greenlee, R. T., Honda, S., Hornbrook, M. C., Epstein, M., Nekhlyudov, L., Pawloski, P. A., Ritzwoller, D. P., Ghai, N. R., Feigelson, H. S., Clancy, H. A., Doria-Rose, V. P., & Kushi, L. H. (2016). The Cancer Research Network: a platform for epidemiologic and health services research on cancer prevention, care, and outcomes in large, stable populations. Cancer causes & control : CCC, 27(11), 1315-1323. https://doi.org/10.1007/s10552-016-0808-4
Chubak, Jessica, et al. "The Cancer Research Network: a platform for epidemiologic and health services research on cancer prevention, care, and outcomes in large, stable populations." Cancer causes & control : CCC vol. 27,11 (2016): 1315-1323. doi: https://doi.org/10.1007/s10552-016-0808-4
Chubak J, Ziebell R, Greenlee RT, Honda S, Hornbrook MC, Epstein M, Nekhlyudov L, Pawloski PA, Ritzwoller DP, Ghai NR, Feigelson HS, Clancy HA, Doria-Rose VP, Kushi LH. The Cancer Research Network: a platform for epidemiologic and health services research on cancer prevention, care, and outcomes in large, stable populations. Cancer Causes Control. 2016 Nov;27(11):1315-1323. doi: 10.1007/s10552-016-0808-4. Epub 2016 Sep 17. PMID: 27639398; PMCID: PMC5868750.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries